Onychomycosis: Predisposed populations and some predictors of suboptimal response to oral antifungal agents

European Journal of Dermatology

Volumn 9, Issue 8, 1999, Pages 633-638

  Gupta, Aditya K ^a   Konnikov, Nellie ^b   Lynde, Charles W ^c   Summerbell, Richard C ^d   Albreski, Douglas ^e   Baran, Robert ^f   De Doncker, Piet ^g   Degreef, Hugo ^h  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b TUFTS MEDICAL CENTER   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Vet Admin Connecticut Hlthcare S   (United States)

^f NAIL DISEASE CENTRE   (France)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Epidemiology; Onychomycosis; Therapy

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; RIFAMPICIN; TERBINAFINE;

ARTICLE; DIABETES MELLITUS; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LEPROSY; ONYCHOMYCOSIS; PERIPHERAL VASCULAR DISEASE; POPULATION RISK; PREDICTION; PSORIASIS; REINFECTION;

ANTIFUNGAL AGENTS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MALE; ONYCHOMYCOSIS; RISK FACTORS;

EID: 0033460268     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. 1. Gupta AK Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994; 30: 677-98.
2. 2. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33.
3. 3. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for superficial mycotic infections of the skin: onychomycosis. J Am Acad Dermatol 1996; 34: 116-21.
4. 4. Gupta AK, De Doncker P, Scher RK, Haneke E, Daniel CR, André J, et al. Itraconazole for the treatment of onychomycosis: an overview. Int J Dermatol 1998; 37: 303-8.
5. 5. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996; 52: 209-24.
6. 6. Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis. Derm Clin 1997; 15: 121-35.
7. 7. Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol 1997; 37: 979-88.
8. 8. De Doncker P, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37: 969-74.
9. 9. Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis. Arch Dermatol 1995; 131: 937-42.
10. 10. Gupta AK, Scher RK. Management of onychomycosis: a North American perspective. Dermatologic Therapy 1997; 3: 58-65.
11. 11. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: S45-50.
12. 12. Tosti A, Piraccini BM, Manani R, et al. Are local and systemic conditions important for the development of onychomycosis? Eur J Dermatol 1998; 8: 41-4.
13. 13. Gupta AK, Daniel CR. Onychomycosis: strategies to reduce failure, reinfection and relapse. Cutis 1998; 62: 189-91.
14. 14. Gupta AK, Daniel CR. Factors that may affect the response of onychomycosis to oral antifungal therapy. Australasian J Dermatol 1998; 39: 222-4.
15. 15. De Doncker P, Degreef H, André J, Piérard G. Why are some patients with onychomycosis still not responding to the newer antifungal agents? The challenge of the future! Fifty-sixth Annual American Academy of Dermatology Meeting, Orlando, Florida, USA. Poster #187. February 27-March 4, 1998.
16. 16. Zaias N, Tosti A, Rebell G, et al. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996; 34: 302-4.
17. 17. Evans EGV. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38: S32-6.
18. 18. Gupta AK, Shear NH. Risk-benefit ratio of the newer oral antifungal agents used to treat onychomycosis. Drug Safety, in press, 1999.
19. 19. English MP, Gibson MD. Studies in the epidemiology of tinea pedis. II. Dermatophytes on the floors of swimming-baths. Br Med J 1959; 1: 1446-8.
20. 20. Philpot CM. Some aspects of the epidemiology of tinea. Mycopathologia 1977; 62: 3-13.
21. 21. English MP, Wethered RR, Duncan EHL. Studies in the epidemiology of tinea pedis. VIII. Fungal infection in a long-stay hospital. Br Med J 1967; 3: 136-9.
22. 22. Raboobee N, Aboobaker J, Peer AK. Tinea pedis et unguium in the Muslim community of Durban, South Africa. Int J Dermatol 1998;' 37: 759-65.
23. 23. Ahye A, Auger P, Joly P. Incidence of occult athlete's foot in swimmers. Eur J Epidemiol 1990; 6: 244-7.
24. 24. Hope YM, Clayton YM, Hay RJ, Noble WC, Elder-Smith JG. Foot infection in coal miners: a reassessment. Br J Derm 1985; 112: 405-13.
25. 25. Ro BI. Chronic mucocutaneous candidiasis. Int J Dermatol 1988; 27: 457-62.
26. 26. Kirkpatrick CH, Smith TK. Chronic mucocutaneous candidiasis: immunologic and antibiotic therapy. Ann Intern Med 1974; 80: 310-20.
27. 27. Jorizzo JL. Chronic mucocutaneous candidiasis. An update. Arch Dermatol 1982; 118: 963-5.
28. 28. Hay RJ, Brostoff J. Immune responses in patients with chronic Trichophyton rubrum infections. Clin Exp Dermatol 1977; 2: 373-80.
29. 29. Hay RJ. Chronic dermatophyte infections. I. Clinical and mycological features. Br J Dermatol 1982; 106: 1-7.
30. 30. Knight AG. A review of experimental human fungus infections. J Invest Dermatol 1972; 59: 354-8.
31. 31. Hanifin JM, Ray LF, Lobitz WC. Immunological reactivity in dermatophytosis. Br J Dermatol 1974; 90: 1-8.
32. 32. Kirkpatrick CH. Host factors in defense against fungal infections. Am J Med 1984: 1-12.
33. 33. McGregor JM, Hamilton AJ, Hay RJ. Possible mechanisms of immune modulation in chronic dermatophytoses: an in vitro study. Br J Dermatol 1992; 127: 233-8.
34. 34. Dahl MV. Suppression of immunity and inflammation by products produced by dermatophytes. J Am Acad Dermatol 1993; 28: S19-23.
35. 35. Jones HE. Immune response and host resistance of humans to dermatophyte infection. J Am Acad Dermatol 1993; 28: S12-8.
36. 36. Zaias N, Rebell G. Chronic dermatophytosis syndrome due to Trichophyton rubrum. Int J Dermatol 1996; 35: 614-7.
37. 37. Mandel EH. Diagnosis: Tinea circinate and onychomycosis (Trichophyton purpureum): resistance to griseofulvin during uncontrolled diabetes. Arch Dermatol 1960; 82: 1027-8.
38. 38. Nelson LM, McNiece KJ. Recurrent Cushing's syndrome with Trichophyton rubrum infection. Arch Dermatol 1959; 80: 700-4.
39. 39. Lewis GM, Hopper ME, Scott MJ. Generalised Trichophyton rubrum infection associated with systemic lymphoblastoma. Arch Dermatol 1953; 67: 247-62.
40. 40. Baer RL, Rosenthal SA, Litt LZ, et al. Experimental investigations on mechanisms producing acute dermatophytosis of feet. J Am Med Assoc 1956; 160: 184-90.
41. 41. Strauss JS, Kligman AM. An experimental study of tinea pedis and onychomycosis of the foot. Arch Dermatol 1957; 76: 70-9.
42. 42. Davis CM, Garcia RL, Riordan JP. Dermatophytes in military recruits. Arch Dermatol 1972; 105: 558-62.
43. 43. Gegory N. Special patient populations: Onychomycosis in the HIV-positive patient. J Am Acad Dermatol 1996; 35: S13-6.
44. 44. Daniel CR, Norton LA, Scher RK. The spectrum of nail disease in patients with human immunodeficiency virus infection. J Am Acad Dermatol 1992; 27: 93-7.
45. 45. Uthayakumar S, Nandwani R, Drinkwater T, Nayagam AT, Darley CR. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 1997; 137: 595-8.
46. 46. Matis WL, Triana A, Shapiro R, Eldred L, Polk F, Hood AF. Dermatologic findings associated with human immunodeficiency virus infection. J Am Acad Dermatol 1987; 17: 746-51.
47. 47. Rosatelli JB, Machado AA, Roselino AMF. Dermatoses among Brazilian HIV-positive patients: correlation with the evolutionary phases of AIDS. Int J Dermatol 1997; 36: 729-39.
48. 48. Ravnborg L, Baastrup N, Svejgaard E. Onychomycosis in HIV-infected patients. Acta Dermatol Venereol 1998; 78: 151-2.
49. 49. Noble RL, Warren RP. Altered T-cell subsets and defective T-cell function in young children with Down's syndrome (trisomy-21). Immunol Invest 1987; 16: 371-82.
50. 50. Nespoli L, Burgio GR, Ugazio AG, et al. Immunological features of Down's syndrome: a review. J Intellectual Disability Research 1993; 37: 543-51.
51. 51. Levin S. The immune system and susceptibility to infections in Down's syndrome. Prog Clin Biol Res 1987: 43-162.
52. 52. Velthius PJ, Nijenhuis M. Treatment of onychomycosis with terbinafine in patients with Down's syndrome. Br J Dermatol 1995; 133: 144-5.
53. 53. Buxton PK, Milne LJR, Prescott, et al. The prevalence of dermatophyte injection in well-controlled diabetics and the response to Trichophyton antigen. Br J Dermatol 1996; 134: 900-3.
54. 54. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, et al. Prevalence and epidemiology of onychomycosis of the toes in diabetic subjects: a multicenter survey. Br J Dermatol 1998; 139: 665-71.
55. 55. Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in abnormal appearing nails in psoriatics compared to non-psoriatics: a multicenter study. Br J Dermatol 1997; 136: 786-9.
56. 56. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists offices in Ontario, Canada-a multicenter survey of 2,001 patients. Int J Dermatol 1998; 36: 783-7.
57. 57. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172-3.
58. 58. Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, Shear NH, De Doncker P, Daniel CR, Elewski BE. The prevalence of onychomycosis in children and treatment strategies. J Am Acad Dermatol 1997; 36: 395-402.
59. 59. Clemens KV, Schar G, Stover EP, Feldman D, Stevens DA. Dermatophyte-hormone relationships: characterization of progesterone-binding specificity and growth inhibition in the genera Trichophyton and Microsporum. J Clin Microbiol 1988; 26: 2110-5.
60. 60. Daniel CR, Gupta AK, Daniel MP, Daniel CM. Two feet-one hand syndrome: A retrospective multicenter survey. Int J Dermatol 1997; 36: 658-60.
61. 61. Hamilton JB, Terada H, Mestler GE. Studies of growth throughout the life span in Japanese: growth and size of nails and their relationship to age, sex, heredity and other factors. J Gerontol 1955; 10: 401-15.
62. 62. Dawber RPR, De Berker D, Baran R. Science of the nail apparatus. In: Baran R Dawber RPR, eds. Diseases of the nails and their management. Blackwell Scientific Publications, Oxford, England, Second Edition, 1994: 1-34.
63. 63. De Doncker P, Piérard GE. Acquired nail beading in patients receiving itraconazole - an indicator of faster nail growth? A study using optical prolifometry. Clin Exp Dermatol 1994; 19: 404-6.
64. 64. Shelley WB, Shelley ED. Portrait of practice. Cutis 1992; 49: 386.
65. 65. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Dermatol Venereol (Stockh) 1996; 76: 82-3.
66. 66. Hay RJ. Chronic dermatophyte infections. In: Verbov J, ed. Superficial fungal infections. MTP Press Limited, Lancaster, UK, 1998: 23-4.
67. 67. Roberts DT, Evans EGV. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189-90.
68. 68. André J, De Doncker P, Ginter G, et al. Intermittent pulse therapy with itraconazole in onychomycosis: an update. Poster presented at the American Academy of Dermatology 51st Annual Meeting, Washington, DC, February 1996.
69. 69. Gupta AK, Jain H, Lynde CW, Summerbell RC. Prevalence of onychomycosis in 15,000 patients visiting dermatologists' offices in London, Ontario, Canada. J Eur Acad Dermatol Venereol 1998; 11 (suppl. 2): S151 (Abstract).
70. 70. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol 1998; 38: S37-41.
71. 71. Elewski BE. Bacterial infection in a patient with onychomycosis. J Am Acad Dermotol 1997; 37: 493-4.
72. 72. Suarez SM, Silvers DN, Scher RK, Pearlstein HH, Averbach R. Histologic evaluation of nail clippings from diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517-9.
73. 73. Machler BC, Kirsner RS, Elgart GW. Routine histologic examination for the diagnosis of onychomycosis: an evaluation of sensitivity and specificity. Cutis 1998; 61: 217-9.
74. 74. Elewski BE, Greer DL. Hendersonula toruloidea and Scytalidium hyalinum. Arch Dermatol 1991; 127: 1041-4.
75. 75. Gupta AK, Elewski BE. Nondermatophyte causes of onychomycosis and superficial mycoses. Cur Topics Med Mycol 1996; 7: 87-97.
76. 76. Sigler L, Congly H. Toenail infection caused by Onychocola canadensis gen.et sp.nov. J Med Vet Mycol 1990; 28: 405-17.
77. 77. Gupta AK, Horgan-Bell CB, Summerbell RC. Onychomycosis associated with Onychocola canadensis 10 case reports and a review of the literature. J Am Acad Dermatol 1998; 39: 410-7.
78. 78. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36: 423-6.
79. 79. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52: 235-7.
80. 80. Stockley IH. Drug Interactions. The Pharmaceutic Press, London, Fourth Edition, 1996.
81. 81. Chin TW, Leob M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Ag Chemother 1995; 39: 1671-5.
82. 82. Itraconazole oral solution package insert Jonssen Pharmaceutica Inc., Titusville, New Jersey, USA, February, 1997.
83. 83. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine, and their management. J Am Acad Dermatol 1999; 41: 237-49.
84. 84. Terbinafine product insert, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, April 1997.
85. 85. Fluconazole package insert, Pfizer Roerig, New York, New York, USA, February 1997.
86. 86. Katz HI, Gupta AK. Oral antifungal drug interactions. Derm Clinics 1997; 15: 535-44.
87. 87. Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytoses correlates with in vitro resistance. Arch Dermatol 1981; 117: 16-9.
88. 88. De Cuyper C. Therapeutic approach of recalcitrant toenail onychomycosis. J Eur Acad Dermatol Venereol 1998; 11 (suppl. 2): S230 (Abstract).
89. 89. Gupta AK, Lynde CW, Konnikov N. Sequential therapy with itraconazole and terbinafine for the management of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 1998; 11 (suppl. 2): 5229-30 (Abstract).
90. 90. Zaug M, Bergstraesser M. Amorolfine in the treatment of anychomycosis and dermatomycoses (an overview). Clin Exp Dermatol 1992; 17: 61-70.
91. 91. Baran R. Amorolfine nail lacquer: a new transungual delivery system for nail mycoses. J Am Med Assoc (Southeast Asia supplement) 1993; 9 (suppl. 4): 5-6.